COVID-19住院患者甲状腺激素水平与疾病严重程度及死亡率的关联
研究发现危重患者游离三碘甲状腺原氨酸(fT3)水平更低,而反向三碘甲状腺原氨酸(rT3)升高程度较轻;fT3、rT3及其乘积与院内死亡风险相关,提示早期评估甲状腺功能对预后判断有价值。
要点
- 危重COVID-19患者fT3水平显著低于非危重患者,rT3升高程度较轻。
- fT3、rT3及fT3×rT3乘积与院内死亡风险独立相关,具备预后预测价值。
- 非甲状腺疾病综合征(fT3<2.0 pg/mL)与死亡风险显著升高相关。
核心结论
- 住院COVID-19患者血清fT3、rT3及fT3×rT3乘积与疾病严重程度和院内死亡相关。
- 早期评估甲状腺功能有助于识别高危COVID-19住院患者。
研究设计与样本
- 中位年龄62(49-75)岁,分为非危重组(181例)和危重组(64例)。
主要发现
- 危重组fT3为2.82(2.46-3.29)pg/mL,低于非危重组的3.09(2.67-3.63)pg/mL(p=0.007)。
- 危重组rT3为0.36(0.28-0.56)ng/mL,低于非危重组的0.51(0.31-0.67)ng/mL(p=0.001)。
- 单因素logistic回归显示院内死亡与fT3(OR 0.47,95%CI 0.29-0.74,p=0.0019)、rT3(OR 0.09,95%CI 0.01-0.49,p=0.006)及fT3×rT3(OR 0.47,95%CI 0.28-0.74,p=0.0026)相关。
- fT3≤2.6 pg/mL和rT3≤0.38 ng/mL分别与3.46和5.94的死亡OR相关;非甲状腺疾病综合征(fT3<2.0 pg/mL)与7.05的死亡OR相关(95%CI 1.78-28.3,p=0.005)。
关键数值与推荐
- fT3的ROC曲线下面积(AUC)为0.66,rT3为0.64,fT3×rT3乘积为0.70。
- rT3×fT3≤1.29与8.08的死亡OR相关(95%CI 3.14-24.2,p<0.0001)。
临床怎么用
- 对住院COVID-19患者可早期检测甲状腺功能,尤其是fT3和rT3。
- fT3、rT3及fT3×rT3乘积可作为预后分层参考指标。
局限性
- 研究为观察性设计,结果需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Illness severity in patients infected with COVID-19 is variable. Methods: Here, we conducted an observational, longitudinal, and prospective cohort study to investigate serum thyroid hormone (TH) levels in adult COVID-19 patients, admitted between June and August 2020, and to determine whether they reflect the severity or mortality associated with the disease. Results: Two hundred forty-five patients [median age: 62 (49-75) years] were stratified into non-critical (181) and critically ill (64) groups. Fifty-eight patients (23.6%) were admitted to the intensive care unit, and 41 (16.7%) died. Sixteen (6.5%) exhibited isolated low levels of free triiodothyronine (fT3). fT3 levels were lower in critically ill compared with non-critical patients [fT3: 2.82 (2.46-3.29) pg/mL vs. 3.09 (2.67-3.63) pg/mL, p = 0.007]. Serum reverse triiodothyronine (rT3) was mostly elevated but less so in critically ill compared with non-critical patients [rT3: 0.36 (0.28-0.56) ng/mL vs. 0.51 (0.31-0.67) ng/mL, p = 0.001]. The univariate logistic regression revealed correlation between in-hospital mortality and serum fT3 levels (odds ratio [OR]: 0.47; 95% confidence interval [CI 0.29-0.74]; p = 0.0019), rT3 levels (OR: 0.09; [CI 0.01-0.49]; p = 0.006) and the product fT3 × rT3 (OR: 0.47; [CI 0.28-0.74]; p = 0.0026). Serum thyrotropin, free thyroxine, and fT3/rT3 values were not significantly associated with mortality and severity of the disease. A serum cutoff level of fT3 (≤2.6 pg/mL) and rT3 (≤0.38 ng/mL) was associated with 3.46 and 5.94 OR of mortality, respectively. We found three COVID-19 mortality predictors using the area under the receiver operating characteristic (ROC) curve (AUC score): serum fT3 (AUC = 0.66), rT3 (AUC = 0.64), and the product of serum fT3 × rT3 (AUC = 0.70). Non-thyroidal illness syndrome (fT3 < 2.0 pg/mL) was associated with a 7.05 OR of mortality ([CI 1.78-28.3], p = 0.005) and the product rT3 × fT3 ≤ 1.29 with an 8.08 OR of mortality ([CI 3.14-24.2], p < 0.0001). Conclusions: This prospective study reports data on the largest number of hospitalized moderate-to-severe COVID-19 patients and correlates serum TH levels with illness severity, mortality, and other biomarkers to critical illness. The data revealed the importance of early assessment of thyroid function in hospitalized patients with COVID-19, given the good prognostic value of serum fT3, rT3, and fT3 × rT3 product. Further studies are necessary to confirm these observations.
引用
- Beltrão FEL, Beltrão DCA, Carvalhal G, et al. Thyroid Hormone Levels During Hospital Admission Inform Disease Severity and Mortality in COVID-19 Patients. Thyroid. 2021. PMID: 34314259. doi:10.1089/thy.2021.0225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。